ASSESSING THE PREFERENCES OF PATIENTS WITH PSORIASIS - A QUANTITATIVE, UTILITY APPROACH

被引:86
作者
ZUG, KA
LITTENBERG, B
BAUGHMAN, RD
KNEELAND, T
NEASE, RF
SUMNER, W
OCONNOR, GT
JONES, R
MORRISON, E
CIMIS, R
机构
[1] DARTMOUTH COLL,HITCHCOCK MED CTR,DEPT MED,DERMATOL SECT,LEBANON,NH 03756
[2] DARTMOUTH COLL,HITCHCOCK MED CTR,CTR EVALUAT CLIN SCI,DEPT COMMUNITY & FAMILY MED,LEBANON,NH 03756
关键词
D O I
10.1001/archderm.131.5.561
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background and Design: Patient preferences for health outcomes can be explicitly assessed and expressed in quantitative terms known as utilities. Three standard methods for utility assessment have been used to quantify patient preferences, but these methods have not previously been applied to skin disease. Eighty-seven patients with psoriasis from a tertiary medical center were interviewed, using an interactive, computer-based utility assessment questionnaire, U-Titer. Utilities for three categories of psoriasis severity and potential adverse outcomes of methotrexate therapy were assessed by the vertical rating scale, time trade-off, and standard gamble. Results: Patients assigned a broad range of utilities for each of the health states. Utilities obtained by the vertical rating scale did not correlate well with utilities obtained by standard gamble or time trade-off methods. However, utilities assessed by standard gamble and time trade-off were not significantly different. Patient characteristics such as age, gender, and education were not correlated with utility and did not explain the variation. Indicators of the patients' disease severity were not predictive of utilities for the assessed health states. The relatively high utility for liver biopsy suggests that there is less patient aversion to the procedure than suspected. Conclusions: Utilities, or quantitative measures of patient preferences for health states, are measurable and vary widely for mild, moderate, and severe psoriasis and possible adverse outcomes of methotrexate treatment. The process of elucidating individual patient utilities for various health outcomes can be used to incorporate patient preferences into the process of clinical decision making. Guidelines that are based solely on severity of symptoms, without input from patients on how they value such symptoms, must be questioned.
引用
收藏
页码:561 / 568
页数:8
相关论文
共 24 条
[1]  
BAUGHMAN RD, 1991, 5TH INT PSOR S SAN F
[2]   GUIDELINES OF CARE FOR PSORIASIS [J].
DRAKE, LA ;
CEILLEY, RI ;
CORNELISON, RL ;
DOBES, WA ;
DORNER, W ;
GOLTZ, RW ;
LEWIS, CW ;
SALASCHE, SJ ;
TURNER, MLC ;
MENTER, A ;
SKINNER, RB ;
ZANOLLI, MD ;
DOBES, WL .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1993, 28 (04) :632-637
[3]  
Eraker S A, 1981, Med Decis Making, V1, P29, DOI 10.1177/0272989X8100100105
[4]   VALIDATION OF SICKNESS IMPACT PROFILE AND PSORIASIS DISABILITY INDEX IN PSORIASIS [J].
FINLAY, AY ;
KHAN, GK ;
LUSCOMBE, DK ;
SALEK, MS .
BRITISH JOURNAL OF DERMATOLOGY, 1990, 123 (06) :751-756
[5]   PSORIASIS - AN INDEX OF DISABILITY [J].
FINLAY, AY ;
KELLY, SE .
CLINICAL AND EXPERIMENTAL DERMATOLOGY, 1987, 12 (01) :8-11
[6]  
FINLAY AY, 1993, BR J DERMATOL S42, V129, P32
[7]   SEVERE PSORIASIS - ORAL THERAPY WITH A NEW RETINOID [J].
FREDRIKSSON, T ;
PETTERSSON, U .
DERMATOLOGICA, 1978, 157 (04) :238-244
[8]  
GROOME PA, 1993, MED DECIS MAKING, V13, P387
[9]  
Holloway C. A., 1979, DECISION MAKING UNCE
[10]  
KNEELAND T, 1993, MED DECIS MAKING, V13, P390